July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Optical coherence tomography angiography changes before and after panretinal photocoagulation in patients with treatment-naïve proliferative diabetic retinopathy
Author Affiliations & Notes
  • Anna Stage Vergmann
    Ophthalmology, Odense University Hospital, Denmark, Odense C, Denmark
    University of Southern Denmark, Odense, Denmark
  • Tien Y Wong
    Singapore National Eye Centre, Singapore
  • Ryo Kawasaki
    Department of Vision Informatics, Osaka University Graduate School of Medicine, Osaka, Japan
    University of Southern Denmark, Odense, Denmark
  • Tunde Peto
    University of Southern Denmark, Odense, Denmark
    School of Medicine, Dentistry and Biomedical Sciences, Queen’s University, Belfast, Belfast, United Kingdom
  • Jakob Grauslund
    Ophthalmology, Odense University Hospital, Denmark, Odense C, Denmark
    University of Southern Denmark, Odense, Denmark
  • Footnotes
    Commercial Relationships   Anna Vergmann, None; Tien Wong, None; Ryo Kawasaki, None; Tunde Peto, None; Jakob Grauslund, None
  • Footnotes
    Support  Velux Foundation
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3010. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Anna Stage Vergmann, Tien Y Wong, Ryo Kawasaki, Tunde Peto, Jakob Grauslund; Optical coherence tomography angiography changes before and after panretinal photocoagulation in patients with treatment-naïve proliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3010.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Fluorescein angiography is traditionally used to determine disease activity in proliferative diabetic retinopathy (PDR), but angiography is invasive and area of leakage over time can be difficult to evaluate. Optical Coherence Tomography Angiography (OCTA) allows non-invasive morphological evaluation of retinal neovascularization (NV) and could present a new method to evaluate PDR-activity. The purpose of this study was to evaluate area of NV, as measured by OCTA, as a marker of disease activity before and after panretinal photocoagulation (PRP) in patients with treatment-naïve PDR.

Methods : This was a prospective study of 10 patients with treatment-naïve PDR. En face OCTA scans (4.5 mm x 4.5 mm, DRI OCT Triton swept source OCT) of NV were performed at baseline (BL) and 3-6 months after PRP, and areas were measured by ImageJ (National Institutes of Health) using the ‘Polygon selections’ tool. Wilcoxon signed-rank test was used to compare area at BL and follow up. The association of area of NV between BL and follow-up (FU) was given by Spearman’s rank correlation coefficient. Progression/regression of NVs was determined by fluorescein angiography and indirect ophthalmoscopy.

Results : Median age was 51 years (range 36-80 years), and 50.0% were male. Median area of NV at BL and FU did not differ (1169.5 µm2 vs. 1153.1 µm2, p=0.17), but they were strongly, positively correlated (rs 0.96, p<0.0001). Four and six patients regressed and progressed in PDR-activity at FU. For those groups, median area of NV at BL and FU were 784.4 and 798.2 µm2 (regression), and 1458.8 and 1607.0 µm2 (progression).

Conclusions : In patients with treatment-naïve PDR, there was a strong correlation between OCTA-measured area of retinal NV before and after PRP. Treatment response differed between smaller and larger NV with a better outcome for the former. This indicates that OCTA may serve as clinically useful tool to measure disease activity and adequacy of treatment response in PDR.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×